
Alcon Inc. is an independent, publicly traded global eye care company with no parent company. It was spun off from Novartis AG in April 2019 and trades on both the NYSE (ALC) and the SIX Swiss Exchange (ALC). Founded in 1945 in Fort Worth, Texas, by pharmacists Robert and William Conron, Alcon is the world's largest eye care device company by revenue, generating approximately $10.2 billion in annual sales.
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Alcon | Alcon Inc. | Publicly traded |
Alcon was founded in 1945 by brothers Robert and William Conron, both pharmacists, in Fort Worth, Texas. The company name is derived from their surname. The Conron brothers concentrated initially on ophthalmic pharmaceutical preparations, products used directly in eye care practice that larger companies were not prioritizing at the time.
Through the 1950s and 1960s, Alcon extended its product range into contact lens care solutions and eye drops. The Opti-Free contact lens solution, launched in later decades, became one of the most widely used lens care products globally. Systane artificial tears, also developed under Alcon, became a widely recognized dry eye treatment brand.
Nestlé acquired Alcon in 1977, providing capital for international expansion. Under Nestlé ownership, Alcon built out manufacturing facilities outside the United States and expanded into surgical equipment for ophthalmology. Novartis began acquiring Alcon from Nestlé in 2008, completing full ownership by 2010 in a deal valued at approximately $52 billion at close. Alcon operated as a division of Novartis for the following nine years.
In June 2018, Novartis announced plans to separate Alcon as an independent company. The spin-off was completed on April 9, 2019. Alcon relocated its global headquarters from Fort Worth to Geneva, Switzerland, and began operating with its own board, management team, and balance sheet.
Since independence, Alcon has pursued acquisitions to expand its product lines. In 2022, Alcon acquired Aerie Pharmaceuticals, a glaucoma drug company, for approximately $770 million. In March 2025, Alcon announced the acquisition of LENSAR, a maker of robotic femtosecond laser systems for cataract surgery, for approximately $356 million. Both acquisitions were funded from Alcon's own balance sheet and credit facilities without Novartis involvement.
What does Alcon own?
Alcon owns a portfolio of eye care brands across two business segments. In Surgical, the company owns intraocular lens brands including Clareon, PanOptix, and AcrySof, surgical equipment brands, and consumable products. In Vision Care, Alcon owns contact lens brands including TOTAL30, PRECISION7, DAILIES, and Air Optix, and ocular health brands including Systane and Tryptyr. The company also owns Aerie Pharmaceuticals, which produces glaucoma treatments.
Is Alcon publicly traded?
Yes, Alcon Inc. trades on the New York Stock Exchange under ticker ALC and on the SIX Swiss Exchange under the same ticker. The company was spun off from Novartis in April 2019 and began trading as an independent company. Alcon is incorporated in Switzerland and headquartered in Geneva.
Who founded Alcon?
Alcon was founded in 1945 by Robert Conron and William Conron in Fort Worth, Texas. The company's name is derived from the first syllables of "Alex" and "Conron." The founders initially focused on manufacturing ophthalmic products, including sterile ophthalmic solutions and instruments for eye surgery. Alcon was later acquired by Nestle in 1977 and then by Novartis in 2010 before being spun off as an independent company in 2019.
Where is Alcon headquartered?
Alcon is headquartered in Geneva, Switzerland. The company was incorporated in Switzerland ahead of its 2019 spin-off from Novartis. Alcon maintains significant operations in Fort Worth, Texas, where it was originally founded, along with manufacturing facilities in Switzerland, the United States, Mexico, Japan, China, India, and Belgium.
How many brands does Alcon own?
Alcon owns multiple eye care brands across its Surgical and Vision Care segments. Key brands include TOTAL30, PRECISION7, DAILIES, Air Optix, Systane, Tryptyr, PanOptix, Clareon, and Aerie Pharmaceuticals products. The company's portfolio is focused exclusively on eye care, with products spanning contact lenses, ocular health treatments, intraocular lenses, and surgical equipment.
Who owns Alcon?
Alcon is a publicly traded corporation owned by its shareholders. Major institutional holders include Vanguard Group, BlackRock, and other large asset managers. Novartis distributed all of its Alcon shares to Novartis shareholders in the April 2019 spin-off, retaining no ownership stake. No single shareholder holds a controlling interest in the company.
What is Alcon's revenue?
In FY2025, Alcon reported net sales of $10.3 billion, up 5% as reported and 4% on a constant currency basis. Diluted earnings per share were $1.98, and core diluted EPS was $3.07. The company generated $2.3 billion in cash from operating activities and $1.7 billion in free cash flow. In Q1 2026, net sales were $2.69 billion, up 10% as reported.
Has Alcon made any recent acquisitions?
Yes, Alcon has been active in acquisitions. In 2025, the company acquired a majority interest in Aurion Biotech for approximately $522 million, completed the acquisition of LumiThera for $124 million, and acquired approximately 91.2% of Cylite Pty Ltd. In March 2025, Alcon agreed to acquire LENSAR for up to $430 million, but terminated the agreement in March 2026. In 2022, Alcon acquired Aerie Pharmaceuticals for approximately $770 million.
Alcon publishes an annual sustainability report under its "Brilliant Planet" environmental framework. As of the 2024 report, 17 of 18 manufacturing sites held ISO 14001:2015 environmental management certification. Approximately 70% of manufacturing sites operate as landfill-free for non-hazardous waste.
Alcon has set targets to reduce absolute Scope 1 and 2 greenhouse gas emissions. The company's 2024 sustainability report documented progress toward these targets but did not claim net-zero certification. No third-party carbon-neutral certification from a body such as Science Based Targets initiative (SBTi) has been confirmed for Alcon's full operations as of May 2025.
Through its "Brilliant Lives" social impact program, Alcon has committed funds and resources to improving vision access in underserved communities. The company reported investing approximately $42 million annually in eye care infrastructure and training in low-income markets.
Alcon's contact lens manufacturing processes use significant volumes of water. The company's sustainability reports document water use by facility but do not claim water-neutral status.
Alcon's Dailies Total1 contact lens received recognition from the American Academy of Optometry at its annual meeting for its water gradient silicone hydrogel technology, which delivers a reported 80% water content at the lens surface. This is a verifiable clinical and technical claim documented in peer-reviewed literature.
Alcon's NGENUITY 3D visualization system has been referenced in peer-reviewed ophthalmology publications as a significant development in vitreoretinal surgery technique, enabling surgeons to operate while viewing a 3D display rather than through an operating microscope eyepiece.
Alcon's PanOptix trifocal intraocular lens was the first trifocal IOL to receive FDA approval for use in the United States, cleared in 2019. This regulatory milestone is a verifiable fact documented in FDA clearance records.
December 2024 Systane recall: Alcon Laboratories issued a voluntary nationwide recall of one lot of Systane Lubricant Eye Drops Ultra PF (Lot 10101) due to potential fungal contamination. The recall was initiated after a consumer complaint identified foreign material inside a sealed single-use vial. The FDA classified the recall and noted that use of contaminated eye drops could cause eye infections that may be vision-threatening. No adverse events were reported at the time of the recall announcement. The affected lot had an expiration date of September 2025.
Aerie Pharmaceuticals drug pricing: Following the 2022 acquisition of Aerie Pharmaceuticals, Alcon assumed the marketing of glaucoma drugs Rocklatan and Rhopressa. Patient advocacy organizations have raised concerns about the pricing of branded glaucoma medications generally, though no specific enforcement action related to these drugs has been announced against Alcon as of May 2025.
Contact lens environmental impact: Industry analysts and environmental researchers have raised concerns about single-use daily contact lens waste, noting that billions of lenses and their packaging are disposed of annually. Alcon is one of the major producers of daily disposable lenses. The company has not announced a formal recycling program for daily disposable lenses in the United States as of May 2025, in contrast to some competitors who have launched such programs.
No major FDA Warning Letters have been issued to Alcon manufacturing facilities as of May 2025, per publicly available FDA inspection records.
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Johnson Johnson | USA | 1987 | Mass market | Global | All Genders | |
| Bausch Lomb | Canada | 1853 | Leader | Global | Unisex | |
| Menicon | Singapore | 2006 | Mass market | Asia pacific | Unisex | |
| Coopercompanies | USA | 1980 | Leader | Global | Unisex | |
| Menicon | Japan | 1951 | Leader | Asia pacific | Unisex |
Healthcare PharmaceuticalsOwned by Johnson & Johnson
Acuvue is the world's leading contact lens brand, owned by Johnson & Johnson Vision Care, a division of Johnson & Johnson. The brand covers daily, weekly, and monthly disposable soft contact lenses sold in more than 100 countries.
Healthcare PharmaceuticalsOwned by Bausch + Lomb Corporation
Global eye health company and contact lens manufacturer founded in 1853, known for ULTRA, Biotrue One Day, and INFUSE lens lines. Public on NYSE and TSX under BLCO.
Healthcare PharmaceuticalsOwned by Menicon Co., Ltd.
Contact lens brand owned by Menicon, headquartered in Singapore, producing biocompatible daily disposable and monthly silicone hydrogel lenses for Asia-Pacific and global markets.
Healthcare PharmaceuticalsOwned by The Cooper Companies, Inc.
Global contact lens manufacturer and division of CooperCompanies, known for Biofinity, MyDay, Clariti, and MiSight myopia management lenses. Strong in toric and multifocal fittings.
Owned by Menicon Co., Ltd.
Japan's first and largest contact lens manufacturer, founded in 1951 in Nagoya. Known for rigid gas permeable lenses, orthokeratology, and expanding daily disposable silicone hydrogel products.
Market Positioning: Alcon competes with 5 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Looking for brands with different ownership structures? These similar brands are not owned by Alcon Inc., giving you alternative choices that support different corporate structures.
Owned by Menicon Co., Ltd.
Japan's first and largest contact lens manufacturer, founded in 1951 in Nagoya. Known for rigid gas permeable lenses, orthokeratology, and expanding daily disposable silicone hydrogel products.
Menicon operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by Bausch + Lomb Corporation
Global eye health company and contact lens manufacturer founded in 1853, known for ULTRA, Biotrue One Day, and INFUSE lens lines. Public on NYSE and TSX under BLCO.
Bausch + Lomb operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by GE HealthCare Technologies Inc.
Independent publicly traded healthcare technology company spun off from General Electric in January 2023, providing medical imaging, diagnostics, and healthcare IT solutions globally.
GE HealthCare operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by Herbalife Ltd.
Global nutrition and weight-management brand owned by Herbalife Ltd. and sold through independent distributors in more than 90 markets.
Herbalife operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by Novo Nordisk
Danish pharmaceutical company specializing in diabetes care and obesity treatment. Founded in 1923, headquartered in Bagsvaerd, Denmark. World leader in diabetes care and a leader in obesity treatment with Ozempic, Wegovy, and the investigational CagriSema. CEO Lars Fruergaard Jorgensen departed in March 2025; interim leadership under board chairman Helge Lund until a permanent CEO is appointed.
Novo Nordisk operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by Pfizer Inc.
American multinational pharmaceutical corporation developing and manufacturing medicines, vaccines, and consumer healthcare products, one of the world's largest pharmaceutical companies.
Pfizer operates independently without a large parent corporation.
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.

Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.

Prescription isotretinoin brand developed by Roche and approved by the FDA in 1982 for severe nodular acne. Roche discontinued the brand name in the United States in 2009; the drug continues as Roaccutane in international markets.

Activase (alteplase) is a prescription thrombolytic medication manufactured by Genentech, a wholly-owned subsidiary of Roche. Used to treat acute ischemic stroke, heart attack, and pulmonary embolism.